Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Real Time Quote from BATS)

$7.30 USD

7.30
711,501

-0.14 (-1.88%)

Updated Oct 8, 2024 02:34 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (BCRX) Outperforming Other Medical Stocks This Year?

Implied Volatility Surging for BioCryst (BCRX) Stock Options

by Zacks Equity Research

Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

Moving Average Crossover Alert: BioCryst Pharmaceuticals

by Zacks Equity Research

BioCryst Pharmaceuticals, Inc. (BCRX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

    Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?

    by Zacks Equity Research

    Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

      BioCryst's Shares March Higher, Can It Continue?

      by Zacks Equity Research

      As of late, it has definitely been a great time to be an investor in BioCryst Pharmaceuticals.

      Is BioCryst Pharmaceuticals (BCRX) Stock Outpacing Its Medical Peers This Year?

      by Zacks Equity Research

      Is (BCRX) Outperforming Other Medical Stocks This Year?

      BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      BioCryst (BCRX) delivered earnings and revenue surprises of 7.69% and 78.23%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

      BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?

      by Zacks Equity Research

      During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease

      Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know

      by Zacks Equity Research

      BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know

      by Zacks Equity Research

      BioCryst Pharmaceuticals (BCRX) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day.

      Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?

      by Zacks Equity Research

      Is (BCRX) Outperforming Other Medical Stocks This Year?

      RedHill's Oncology Candidate to be Tested for Coronavirus

      by Zacks Equity Research

      RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.

      Top Ranked Momentum Stocks to Buy for April 20th

      by Zacks Equity Research

      Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th

      Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.

      BioCryst Begins Study on Galidesivir for Coronavirus Infection

      by Zacks Equity Research

      BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.

      BioCryst Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      BioCryst Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

      The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

      by Zacks Equity Research

      The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore

      Tirthankar Chakraborty headshot

      After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys

      by Tirthankar Chakraborty

      After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.

      Amneal (AMRX) Catches Eye: Stock Jumps 6.7%

      by Zacks Equity Research

      Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

      Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet

      by Zacks Equity Research

      Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.

      Sejuti Banerjea headshot

      7 Great Stocks for a Small Budget

      by Sejuti Banerjea

      Take advantage of panic selling with these 7 cheap stocks.

      BioCryst (BCRX) Upgraded to Strong Buy: Here's Why

      by Zacks Equity Research

      BioCryst (BCRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

      Implied Volatility Surging for BioCryst (BCRX) Stock Options

      by Zacks Equity Research

      Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.

      Top Ranked Momentum Stocks to Buy for March 9th

      by Zacks Equity Research

      Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 9th

      BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates

      by Zacks Equity Research

      BioCryst (BCRX) delivered earnings and revenue surprises of 92.00% and 230.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?